Media coverage about Depomed (NASDAQ:DEPO) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Depomed earned a news impact score of 0.21 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 47.384410200911 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the headlines that may have impacted Accern’s analysis:

How to Become a New Pot Stock Millionaire

Shares of Depomed (NASDAQ DEPO) opened at $7.02 on Friday. The firm has a market cap of $457.12, a PE ratio of -4.31 and a beta of 1.10. The company has a debt-to-equity ratio of 3.21, a current ratio of 0.74 and a quick ratio of 0.70. Depomed has a 1 year low of $4.31 and a 1 year high of $16.29.

Depomed (NASDAQ:DEPO) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.05. The firm had revenue of $94.41 million for the quarter, compared to the consensus estimate of $88.75 million. Depomed had a negative net margin of 26.92% and a negative return on equity of 45.19%. research analysts anticipate that Depomed will post -1.03 earnings per share for the current fiscal year.

A number of research analysts have issued reports on the stock. ValuEngine raised shares of Depomed from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 5th. Piper Jaffray Companies reissued a “hold” rating and set a $8.00 price objective on shares of Depomed in a research report on Thursday, March 1st. BidaskClub raised shares of Depomed from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Roth Capital set a $10.00 price objective on shares of Depomed and gave the company a “buy” rating in a research report on Friday, March 2nd. Finally, Royal Bank of Canada set a $9.00 price objective on shares of Depomed and gave the company a “hold” rating in a research report on Thursday, December 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. Depomed presently has a consensus rating of “Hold” and an average target price of $9.56.

In other news, SVP Matthew M. Gosling sold 45,519 shares of the company’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $6.58, for a total value of $299,515.02. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.59% of the stock is owned by corporate insiders.

WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Depomed (NASDAQ:DEPO) Stock Price” was first posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.mareainformativa.com/2018/03/16/depomed-depo-receiving-somewhat-positive-media-coverage-accern-reports-updated-updated-updated.html.

Depomed Company Profile

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Insider Buying and Selling by Quarter for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.